Déclaration d'accessibilité Sauter la navigation
  • Ressources
  • Journalistes
  • Relations investisseurs
  • Webdiffusion
  • English
  • mon CNW 
    • Ouvrir une session
    • Créez un compte
  • Ouvrir une session
  • Inscription
  • Envoyer
Cision Canada
  • Nouvelles
  • Produits
  • Nous joinder
Recherche
When typing in this field, a list of search results will appear and be automatically updated as you type.

Rechercher votre contenu...

Aucun résultat trouvé. Modifiez les termes de votre recherche et réessayez.

News Releases

view all
    Recherche avancée
    • Communiqués
        • Parcourir les communiqués

        • Tous les communiqués de presse
        • Tous les communiqués de sociétés publiques
        • Parcourir tous les communiqués

        • Galerie multimédia

        • Tous les communiqués avec multimédia
        • Tous les communiqués avec photos
        • Tous les communiqués avec vidéos
        • Voir toute la Galerie multimédia

        • Sujets d'actualité

        • Voir tous les sujets d'actualité
    • Affaires
        • Affaires Générales

        • Activités d'externalisation
        • Annonces relatives au personnel
        • Communiqués salon professionnel
        • Enquêtes, sondages et recherches
        • Expansion d'entreprise
        • Immobilier commercial
        • Immobilier résidentiel
        • Investissement socialement responsable
        • Licenciement
        • Nécrologie
        • Nouveaux produits et services
        • Récompenses
        • Ressources humaines et gestion des effectifs
        • Résultats financiers
        • Services aux petites entreprises
        • Transactions immobilières
        • Survol, Affaires Générales

        • Voir tout Affaires Générales

        • Divertissement et médias

        • Art
        • Divertissement
        • Film
        • Livres
        • Magazines
        • Musique
        • Publicité
        • Radio & Baladodiffusion
        • Services de publication et d'information
        • Télévision
        • Survol, Divertissement et médias

        • Voir tout Divertissement et médias

        • Secteur de l’automobile et du transport

        • Aérospatiale, défense
        • Automobile
        • Chaîne logistique / Logistique
        • Compagnies aériennes & Aviation
        • Fret aérien
        • Maritime & Construction navale
        • Tourisme et Voyages
        • Transport, camionnage et de chemin de fer
        • Transports routiers
        • Voies ferrées et transport intermodal
        • Survol, Secteur de l’automobile et du transport

        • Voir tout Secteur de l’automobile et du transport

        • Services financiers et investissements

        • Accords financiers
        • Acquisitions, fusions et rachats
        • Activisme actionnarial
        • Annonces de conférence de presse
        • Assurance
        • Capital de risque
        • Coentreprises
        • Contrats
        • Cryptomonnaie
        • Dividendes
        • Émission d'actions
        • Faillite
        • Fonds communs
        • Fractionnement d'actions
        • Immobilier
        • Nouvelles et dossiers
        • Obligations et actions
        • Opinions d'investissement
        • Placement privé
        • Prévisions de résultats & projections
        • Rapports des ventes
        • Restructuration & recapitalisation
        • Résultats financiers
        • Services bancaires & financiers
        • Survol, Services financiers et investissements

        • Voir tout Services financiers et investissements

        • Technologies des affaires

        • Analyse de données
        • Automatisation de la conception électronique
        • Chaîne de blocs
        • Commerce électronique
        • Composants électroniques
        • Informatique et électronique
        • Logiciel informatique
        • Matériel informatique
        • Nanotechnologie
        • Périphériques
        • Réseaux
        • Sécurité haute technologie
        • Semi-conducteurs
        • Technologie de radiodiffusion
        • Technologie financière
        • Technologie Internet
        • Survol, Technologies des affaires

        • Voir tout Technologies des affaires

    • Sciences et technologie
        • Énergie et ressources naturelles

        • Chimie
        • Commodités
        • Découvertes en matière de pétrole et de gaz
        • Énergies alternatives
        • Fabrication générale
        • Gaz
        • Mines
        • Mines & Métaux
        • Pétrole & Énergie
        • Services d'eau
        • Services d'électricité
        • Survol, Énergie et ressources naturelles

        • Voir tout Énergie et ressources naturelles

        • Environnement

        • Catastrophes naturelles
        • Conservation & Recyclage
        • Politique environnementale
        • Problèmes environnementaux
        • Produits et services environnementaux
        • Technologie verte
        • Survol, Environnement

        • Voir tout Environnement

        • Industries lourdes et manufacturières

        • Aéronautique & Défense
        • Agriculture
        • Chimie
        • Construction & Bâtiment
        • CVC (Chauffage, ventilation et climatisation)
        • Fabrication générale
        • Machinerie
        • Machines-outils, travail des métaux et métallurgie
        • Métaux précieux
        • Mine
        • Mines & Métaux
        • Papier, produits forestiers et conteneurs
        • Tabac
        • Textiles
        • Survol, Industries lourdes et manufacturières

        • Voir tout Industries lourdes et manufacturières

        • Technologie de consommation

        • Analyse de données
        • Chaîne de blocs
        • Chaîne logistique / Logistique
        • Commerce électronique
        • Communications sans fil
        • Cryptomonnaie
        • Divertissement mobile
        • Électronique de consommation
        • Infonuagique / Internet des objets
        • Informatique et électronique
        • Intelligence artificielle
        • Jeux électroniques
        • Logiciel informatique
        • Matériel informatique
        • Médias sociaux
        • Multimédia & Internet
        • Périphériques
        • STIM (Science, technologie, ingénierie, mathématiques)
        • Technologie financière
        • Survol, Technologie de consommation

        • Voir tout Technologie de consommation

        • Télécommunications

        • Carrières et services
        • Communications sans fil
        • Divertissement mobile
        • Équipement de télécommunication
        • Industrie de la télécommunication
        • Périphériques
        • Réseaux
        • VoIP (voix sur IP)
        • Survol, Télécommunications

        • Voir tout Télécommunications

    • Santé et style de vie
        • Divertissement et médias

        • Art
        • Divertissement
        • Film
        • Livres
        • Magazines
        • Musique
        • Publicité
        • Radio & Baladodiffusion
        • Services de publication et d'information
        • Télévision
        • Survol, Divertissement et médias

        • Voir tout Divertissement et médias

        • Produits de consommation et vente au détail

        • Aliments biologiques
        • Aliments et boissons
        • Animaux et animaux domestiques
        • Bières, vins et spiritueux
        • Bijoux
        • Boissons
        • Boissons non-alcoolisées
        • Cannabis
        • Commerce
        • Jouets
        • Ménages, Consommateurs, Cosmétiques
        • Meubles et ameublement
        • Mode
        • Produits cosmétiques et soins personnels
        • Produits d'entretien domestique
        • Produits de bureau
        • Rappels de produit
        • Rénovation domiciliaire
        • Restaurants
        • Services nuptiaux
        • Supermarchés
        • Survol, Produits de consommation et vente au détail

        • Voir tout Produits de consommation et vente au détail

        • Santé

        • Approbation médicale internationale
        • Assurance santé
        • Biométrique
        • Biotechnologie
        • Conditionnement physique / Mieux-être
        • Contrôle des infections
        • Dentisterie
        • Équipement médical
        • Essais cliniques & de Découvertes Médicales
        • Homologation de la FDA
        • Médecines complémentaires
        • Pharmaceuticals médicaux
        • Pharmaceutiques
        • Santé mentale
        • Soins de santé & hôpitaux
        • Survol, Santé

        • Voir tout Santé

        • Sports

        • Équipements et accessoires de sport
        • Événements sportifs
        • Plein air, camping, randonnée pédestre
        • Sports en général
        • Survol, Sports

        • Voir tout Sports

        • Tourisme et Voyages

        • Hôtels et stations
        • Hôtels et stations
        • Industrie du voyage
        • Loisirs et tourisme
        • Parcs d'attraction et attractions touristiques
        • Plein air, camping, randonnée pédestre
        • Trafic aérien de passagers
        • Survol, Tourisme et Voyages

        • Voir tout Tourisme et Voyages

    • Politique et intérêt public
        • Politique et intérêt public

        • Actualités, tendances, analyses économiques
        • Actualités syndicales
        • Bien-être de l'animal
        • But non lucratif
        • Catastrophes naturelles
        • Direction & Agence fédérale exécutif
        • Éducation
        • Environnement
        • Gouvernement européen
        • Homologation de la FDA
        • Législation fédérale et nationale
        • Opinion du groupe de défense des droits
        • Politique commerciale
        • Politique étrangère
        • Politique fédérale
        • Politique intérieure
        • Politique municipale
        • Politique provinciale
        • Questions juridiques
        • Responsabilité sociale de l'entreprise
        • Sécurité intérieure
        • Sécurité publique
        • Survol, Politique et intérêt public

        • Voir tout Politique et intérêt public

    • Société
        • Société

        • Actualités liées aux Afro-américains
        • Actualités liées aux Asiatiques
        • Actualités liées aux enfants
        • Actualités liées aux femmes
        • Actualités liées aux personnes handicapées
        • Actualités orientées vers les hispaniques
        • Anciens combattants
        • Autochtones, Premières Nations et Amérindiens
        • Diversité, équité & inclusion
        • Intérêt des hommes
        • Lesbienne, Homosexuel, Bisexuel
        • Personnes du troisième âge
        • Religion
        • Survol, Société

        • Voir tout Société

    • Recherche avancée
    • Découvrir la plateforme
    • Planifier des campagnes
    • Créer avec l'IA
    • Diffuser des communiqués
    • Mesurer vos résultats
    • Amplifier le contenu
    • Devenir un client
    • Demandez une démo
    • Bureaux d'édition
    • Partenariats
    • Renseignements généraux
    • Médias
    • Bureaux Mondiaux
    • Hamburger menu
    • Cision Canada
    • Envoyer
    • EN
      • Téléphone

      • 877-269-7890 de 8h00 à 22h00

      • Contactez Cision
      • Contactez Cision

        877-269-7890
        de 8h00 à 22h00

    • Rechercher votre contenu...

      Aucun résultat trouvé. Modifiez les termes de votre recherche et réessayez.

      News Releases

      view all
      Close menu
    • Nouvelles
    • Produits
    • Nous joinder
      • Envoyez un communiqué
      • Inscription
      • Ressources
      • Blogue
      • Journalistes
      • Webdiffusion
      • RGPD
      • 3 Communiqués
      • 5 Affaires
      • 5 Sciences et technologie
      • 5 Santé et style de vie
      • 1 Politique et intérêt public
      • 1 Société
      • Envoyez un communiqué
      • Inscription
      • Ressources
      • Blogue
      • Journalistes
      • Webdiffusion
      • RGPD
      • Découvrir la plateforme
      • Planifier des campagnes
      • Créer avec l'IA
      • Diffuser des communiqués
      • Mesurer vos résultats
      • Amplifier le contenu
      • Envoyez un communiqué
      • Inscription
      • Ressources
      • Blogue
      • Journalistes
      • Webdiffusion
      • RGPD
      • Devenir un client
      • Demandez une démo
      • Bureaux d'édition
      • Partenariats
      • Renseignements généraux
      • Médias
      • Bureaux Mondiaux
      • Envoyez un communiqué
      • Inscription
      • Ressources
      • Blogue
      • Journalistes
      • Webdiffusion
      • RGPD
      Close submenu (Communiqués) Communiqués
      • Parcourir les communiqués
      • Galerie multimédia
      • Sujets d'actualité
      Close submenu (Affaires) Affaires
      • Affaires Générales
      • Divertissement et médias
      • Secteur de l’automobile et du transport
      • Services financiers et investissements
      • Technologies des affaires
      Close submenu (Sciences et technologie) Sciences et technologie
      • Énergie et ressources naturelles
      • Environnement
      • Industries lourdes et manufacturières
      • Technologie de consommation
      • Télécommunications
      Close submenu (Santé et style de vie) Santé et style de vie
      • Divertissement et médias
      • Produits de consommation et vente au détail
      • Santé
      • Sports
      • Tourisme et Voyages
      Close submenu (Politique et intérêt public) Politique et intérêt public
      • Politique et intérêt public
      Close submenu (Société) Société
      • Société

      Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

      Cellebrite Logo (PRNewsfoto/Cellebrite)

      Nouvelles fournies par

      Cellebrite

      11 févr, 2026, 07:00 ET

      Partager cet article

      Partager cet article


      Total ARR grew 21% to $480.8 million; Revenue grew 18% to $128.8 million

      Net income of $21.3 million supports non-GAAP net income of $36.7 million and adjusted EBITDA of $38.3 million, 29.8% adjusted EBITDA margin

      TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2026 /CNW/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2025.

      "Cellebrite closed 2025 with a solid fourth quarter that capped a year of meaningful strategic progress," stated Thomas E. Hogan, Cellebrite's CEO. "We cemented our Inseyets offering as the gold standard in digital forensics, drove strong adoption of our SaaS and cloud-based offerings, completed our first major acquisition and added important talent across the Company. Despite a challenging U.S. Federal spending environment, we drove 21% ARR growth in 2025, which reflects expansion across all of our major geographies and our flagship offerings, as well as the modest contribution from Corellium. Our success in growing the top line while expanding profit margins and generating outstanding free cash flow is a direct byproduct of the value of our platform, the strength of customer relationships and our ongoing commitment to thoughtful commitment to thoughtful spending and optimized resource allocation."

      Hogan added, "Our 2026 outlook reflects our conviction in accelerated ARR growth. The positive macro tailwinds for our business persist. We remain well positioned to expand our relationships across global law enforcement, defense and intelligence, and the private sector. We enter 2026 with a wide range of new and ongoing opportunities for growth including the continuation of Inseyets conversions, our new advanced unlock capabilities, broad adoption of our Guardian Forensics combined with the upcoming launch of Guardian Investigate, an expanding suite of AI-powered analytics, the global distribution of Corellium solutions across both the private and public sectors, the anticipated rebound within the U.S. Federal segment, our new, expected leadership position in Drone Forensics and our increased investment in the Defense and Intelligence sector. As always, we remain committed to responsible profitability and our corresponding strength in free cash flow. I am proud of this team and product of significant role we continue to play in keeping our nations, communities and businesses safe."

      Fourth-Quarter 2025 Financial Highlights

      • Revenue of $128.8 million, up 18% year-over-year
      • Subscription revenue was $115.5 million, up 21% year-over-year
      • Total Annual Recurring Revenue (ARR) of $480.8 million, up 21% year-over-year
        • Total ARR includes $16.1 million in ARR from Corellium, which was acquired by Cellebrite on December 1, 2025. Excluding Corellium's ARR, Cellebrite's ARR grew organically by 17% to $464.7 million.
      • Recurring revenue dollar-based net retention rate of 116%
      • GAAP gross profit and gross margin of $109.1 million and 84.7%, respectively; Non-GAAP gross profit and gross profit margin of $110.8 million and 86.0%, respectively
      • GAAP net income of $21.3 million; Non-GAAP net income of $36.7 million
      • GAAP diluted earnings per share of $0.08; Non-GAAP diluted earnings per share of $0.14
      • Adjusted EBITDA and Adjusted EBITDA margin of $38.3 million and 29.8%, respectively

      Full-Year 2025 Financial Highlights

      • Revenue of $475.7 million, up 19% year-over-year
      • Subscription revenue was $427.0 million, a 21% year-over-year increase
      • GAAP gross profit and gross margin of $400.5 million and 84.2%, respectively; Non-GAAP gross profit and gross profit margin of $404.6 million and 85.1%, respectively
      • GAAP net income of $78.3 million; Non-GAAP net income of $130.5 million
      • GAAP diluted earnings per share of $0.31; Non-GAAP diluted earnings per share of $0.51
      • Adjusted EBITDA and adjusted EBITDA margin of $127.6 million and 26.8%, respectively

      Recent Business Highlights

      Cellebrite to Acquire SCG Canada, Adding Leading Portable Drone Forensics Capability

      • Cellebrite also announced today its agreement to acquire SCG Canada Inc., a leading provider of hand-held digital forensics solutions that enables access to dozens of the most common Unmanned Aerial Vehicles (UAVs) for extraction, decoding and visualization of important forensic artifacts.
        • This acquisition is expected to further broaden Cellebrite's digital forensics capabilities for collecting and reviewing data from a fast-growing category of digital witnesses. Usage of drones around the globe is surging with global spending on drones expected to grow 20% to $53.5 billion in 2026. While drones have a myriad of constructive use cases, they also bring potential for harm and the pursuit of crime. In the US alone, in 2025 there were an estimated 1.2M drone violations making forensics and mitigations a critical element of balancing the global proliferation of drones.
        • "We believe drone data and artifacts could emerge over the coming years as the second most valuable data source behind mobile/cell phones in the pursuit of justice and safety," said Thomas Hogan. "This applies to multiple customer cohorts including national defense, local law enforcement and private sector businesses focused on securing the air space around critical infrastructure, and dense locations such as airports and sports venues. This represents a modest but important move to further enhance Cellebrite's overall value proposition and further elevate the impact of our AI-powered platform for multi-data source analysis – a critical component of modern-day investigations and intelligence gathering."
        • Once this transaction is completed, Cellebrite customers focused on Defense and Intelligence will benefit from the addition of a highly portable, battery-powered solution for rapid access and visualization of mission-critical data at the point of collection – capabilities that aid smarter, faster decisions that can ultimately save lives. Additionally, law enforcement agencies around the world will gain a valuable forensic capability as they see increasing use of commercially available drones for a wide range of nefarious purposes such as smuggling contraband across borders and into jails, as well as disrupting air travel, large gatherings and public infrastructure.
        • The deal is expected to close later this quarter, subject to customary closing conditions. Terms of the transaction were not disclosed.

      Innovation

      • Digital Forensics: Cellebrite ended 2025 with approximately 55% of its installed digital forensics license base converted to Inseyets, which exceeded the Company's original target of 50% and further validates Inseyets' market and technology leadership. Cellebrite has also continued to broaden its mobile phone access capabilities across Android, Apple iOS and feature phones with anticipated innovations scheduled for general availability over the next several months.
      • AI: Cellebrite has continued to increase its investment in AI. The Company further broadened its AI research and engineering teams to advance the Company's machine learning models, generative AI features and agentic AI capabilities. Cellebrite also continued to build out its AI layer that leverages an expanding AI agent framework that is embedded within its Cellebrite SaaS platform. In addition, Cellebrite recently established an AI Innovation Center to augment the ongoing expansion of its portfolio. Some of Cellebrite's newest AI-enabled features will be embedded in its Guardian Investigate solution, which is designed to help investigative teams build stronger case narratives, collaborate seamlessly in a secure, unified workspace, and analyze a broad range of evidence and file types from digital forensics data, video, call detail records, and open-source intelligence to case records, license plate reader information, ballistics and geolocation data. Guardian Investigate is currently in limited release with general availability anticipated in early spring 2026.

      Go-To-Market

      • On February 5, 2026, Cellebrite published its 2026 Industry Trends Survey, highlighting data-driven insights into the key challenges, shifts and opportunities shaping digital investigations across the public and private sectors worldwide.

      Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results.

      Financial Outlook

      David Barter, Cellebrite's CFO, said, "Our fourth quarter 2025 performance underscores the resilience of our model – solid ARR expansion, sustained subscription momentum especially with our SaaS and cloud-enabled solutions, and outstanding free cash flow generation. Cellebrite moves into 2026 well positioned to scale efficiently and reaccelerate its ARR growth rate. As we continue to thoughtfully allocate capital to drive durable long-term growth, we plan to maintain strong operating profitability and a 30%-plus free cash flow margin in 2026 despite the transitory impacts associated with an unfavorable FX environment." 

      The Company's first-quarter and full-year 2026 financial expectations are as follows:



      First-Quarter 2026 Expectations


      Full-Year 2026 Expectations



      (as of 02/11/26)


      (as of 02/11/26)

      ARR


      $491 million - $493 million


      $567 million - $573 million

      Annual Growth


      20% - 21%


      18% - 19%

      Revenue


      $126 million - $128 million


      $565 million - $571 million

      Annual Growth


      18% - 20%


      19% - 20%

      Adjusted EBITDA


      $26 million - $28 million


      $149 million - $155 million

      Adjusted EBITDA margin


      21%-22%


      26% - 27%

      Conference Call Information
      Cellebrite will host a live conference call and webcast later this morning to review the Company's fourth-quarter 2025 financial results and discuss its full-year 2026 outlook. Pertinent details include:

      Date:


      Wednesday, February 11, 2026

      Time:


      8:30 a.m. ET

      Call-In Number:


      203-518-9814 / 800-274-8461

      Conference ID:


      CLBTQ425

      Event URL:


      https://investors.cellebrite.com/events/event-details/cellebrite-q4-2025-financial-results-conference-call-webcast

      Webcast URL:


      https://edge.media-server.com/mmc/p/v9sjjqnr

      In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company's investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.

      Non-GAAP Financial Information and Key Performance Indicators
      This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP EPS and Adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financial measures, are not prepared in accordance with GAAP.

      The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility into the underlying performance of its business:

      • Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;
      • Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition;
      • Acquisition-related expenses and executive severance expenses relate to the cash component of contractual severance due to our former CEO and CFO, all of which are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
      • To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
      • Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and
      • Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company's current operations and affect financial income.

      Free cash flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or used in our operations that, after the investments in property and equipment, can be used for strategic initiatives.

      Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.

      A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.

      In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.

      This press release also includes key performance indicators, including annual recurring revenue and dollar-based retention rate.

      Annual recurring revenue ("ARR") is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impacted by contract start and end dates and renewal rates.

      Dollar-based net retention rate ("NRR") is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.

      References to Websites and Social Media Platforms
      References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

      Caution Regarding Forward Looking Statements
      This document includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "will," "appear," "approximate," "foresee," "might," "possible," "potential," "believe," "could," "predict," "should," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financial information for the first quarter of 2026 and for fiscal year 2026 including those statements with respect to our 2026 outlook reflecting our conviction in accelerated ARR growth, quarterly and full-year 2026 revenue and annual recurring revenue, profitability, earnings and free cash flow, the anticipated rebound within the U.S. Federal segment, the belief that drone data and artifacts could emerge over the coming years as the second most valuable data source behind mobile/cell phones in the pursuit of justice and safety, the customer benefits associated with the acquisition of SCG Canada and the successful closing of the acquisition later this quarter, as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite's business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's digital investigation solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled "Risk Factors" in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

      About Cellebrite
      Cellebrite's (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite's AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite's technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com.   

      Contacts:

      Investors Relations
      Andrew Kramer
      Vice President, Investor Relations
      [email protected]
      +1 973.206.7760

      Media
      Victor Cooper
      Sr. Director of Corporate Communications + Content Operations
      [email protected]
      +1 404.804.5910

      Cellebrite DI Ltd. 
      Fourth-Quarter 2025 Results Summary
      (U.S. Dollars in thousands)



      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024









      Revenue

      128,821


      109,049


      475,675


      401,203

      Gross profit

      109,130


      91,425


      400,503


      338,610

        Gross margin

      84.7 %


      83.8 %


      84.2 %


      84.4 %

      Operating income

      20,805


      15,727


      66,480


      56,906

        Operating margin

      16.2 %


      14.4 %


      14.0 %


      14.2 %

      Net income (loss)

      21,261


      19,269


      78,326


      (283,007)

      Cash flow from operating activities

      86,811


      65,967


      173,544


      132,171









      Non-GAAP Financial Data:








      Operating income

      36,498


      26,928


      120,663


      92,119

        Operating margin

      28.3 %


      24.7 %


      25.4 %


      23.0 %

      Net income

      36,694


      26,123


      130,506


      97,761

      Adjusted EBITDA

      38,331


      28,793


      127,631


      99,377

      Adjusted EBITDA margin

      29.8 %


      26.4 %


      26.8 %


      24.8 %

      Cellebrite DI Ltd. 
      Condensed Consolidated Balance Sheets
      (U.S. Dollars in thousands)




      December 31,


      December 31,



      2025


      2024

      Assets





      Current assets





      Cash and cash equivalents


      $            124,457


      $            191,659

      Short-term deposits


      161,049


      153,746

      Marketable securities


      151,544


      101,818

      Trade receivables (net of allowance for credit losses of $506 and $594 as of December 31, 2025 and
      December 31, 2024, respectively)


      104,972


      82,358

      Prepaid expenses and other current assets


      19,630


      23,246

      Contract acquisition costs


      6,595


      5,827

      Inventories


      7,603


      8,939

      Total current assets


      575,850


      567,593






      Non-current assets





      Other non-current assets


      14,618


      7,682

      Marketable securities


      97,959


      36,601

      Deferred tax assets, net


      10,880


      11,072

      Property and equipment, net


      22,209


      16,995

      Operating lease right-of-use assets, net


      16,308


      10,604

      Intangible assets, net


      81,469


      11,306

      Goodwill


      119,559


      28,714

      Total non-current assets


      363,002


      122,974

      Total assets


      $            938,852


      $            690,567






      Liabilities and shareholders' equity





      Current Liabilities





      Trade payables


      $              16,834


      $               11,077

      Other accounts payable and accrued expenses


      71,244


      63,330

      Deferred revenues


      277,583


      216,970

      Operating lease liabilities


      3,996


      4,125

      Total current liabilities


      369,657


      295,502






      Long-term liabilities





      Other long-term liabilities


      16,677


      6,954

      Deferred revenues


      49,526


      45,247

      Operating lease liabilities


      18,674


      6,844

      Total long-term liabilities


      84,877


      59,045

      Total liabilities


      454,534


      354,547






      Shareholders' equity 





      Share capital


      *)


      *)

      Additional paid-in capital


      568,721


      498,883

      Treasury share, NIS 0.00001 par value; 41,776 ordinary shares


      (85)


      (85)

      Accumulated other comprehensive income


      2,220


      2,086

      Accumulated deficit


      (86,538)


      (164,864)

      Total shareholders' equity


      484,318


      336,020

      Total liabilities and shareholders' equity


      $            938,852


      $            690,567


      *) Less than 1 USD

      Cellebrite DI Ltd. 
      Condensed Consolidated Statements of Income
      (U.S. Dollars in thousands, except share and per share data)



      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024









      Revenue:








      Subscription services

      $             89,068


      $             73,848


      $           330,765


      $           271,028

      Term-license

      26,426


      21,220


      96,245


      82,007

      Other non-recurring

      4,564


      6,293


      17,771


      17,285

      Professional services  

      8,763


      7,688


      30,894


      30,883

      Total revenue

      128,821


      109,049


      475,675


      401,203









      Cost of revenue:








      Subscription services

      10,502


      7,156


      37,461


      26,004

      Term-license

      87


      --


      87


      --

      Other non-recurring

      4,327


      4,865


      15,617


      16,200

      Professional services

      4,775


      5,603


      22,007


      20,389

      Total cost of revenue 

      19,691


      17,624


      75,172


      62,593









      Gross profit

      $           109,130


      $             91,425


      $           400,503


      $           338,610









      Operating expenses:








      Research and development

      29,865


      25,599


      113,877


      98,415

      Sales and marketing

      38,561


      35,524


      154,814


      132,389

      General and administrative

      19,899


      14,575


      65,332


      50,900

      Total operating expenses

      $             88,325


      $             75,698


      $           334,023


      $           281,704









      Operating income

      $             20,805


      $             15,727


      $             66,480


      $             56,906

      Financial income (expense), net

      5,466


      4,170


      24,198


      (332,890)

      Income (loss) before tax

      26,271


      19,897


      90,678


      (275,984)

      Tax expense

      5,010


      628


      12,352


      7,023

      Net income (loss)

      $             21,261


      $             19,269


      $             78,326


      $         (283,007)









      Earnings (losses) per share








      Basic

      $                  0.09


      $                  0.08


      $                  0.32


      $                (1.35)

      Diluted

      $                  0.08


      $                  0.08


      $                  0.31


      $                (1.35)









      Weighted average shares outstanding








      Basic

      245,282,244


      233,248,045


      241,626,316


      209,471,827

      Diluted

      251,501,118


      247,353,640


      249,903,126


      209,471,827









      Other comprehensive (loss) income:








      Unrealized (loss) income on hedging transactions

      (377)


      261


      1,115


      (487)

      Unrealized income (loss) on marketable securities

      16


      (411)


      317


      113

      Currency translation adjustments

      122


      1,820


      (1,298)


      1,410

      Total other comprehensive (loss) income, net of tax

      (239)


      1,670


      134


      1,036

      Total other comprehensive income (loss)

      $             21,022


      $             20,939


      $             78,460


      $         (281,971)

      Cellebrite DI Ltd.
      Condensed Consolidated Statements of Cash Flow
      (U.S. Dollars in thousands, except share and per share data)




      For the three months ended


      For the year ended



      December 31,


      December 31,



      2025


      2024


      2025


      2024










      Cash flow from operating activities:


















      Net income (loss)


      $             21,261


      $             19,269


      $           78,326


      $       (283,007)

      Adjustments to reconcile net income to net cash provided
      by operating activities:









      Share-based compensation and RSU's


      11,997


      9,269


      44,892


      30,575

      Amortization of premium, discount and accrued interest
      on marketable securities


      (158)


      (866)


      (2,371)


      (2,904)

      Depreciation and amortization


      3,941


      2,729


      11,867


      10,607

      Disposal and write-off of property and equipment


      554


      --


      554


      --

      Abandonment of right‑of‑use assets and disposal of
      leasehold improvements


      1,760


      --


      1,760


      --

      Interest income from short-term deposits


      (1,747)


      (2,836)


      (8,164)


      (10,736)

      Deferred tax assets, net


      1,899


      (1,813)


      75


      (4,015)

      Remeasurement of Warrant liability


      --


      --


      --


      110,664

      Remeasurement of Restricted Sponsor Shares liability


      --


      --


      --


      65,889

      Remeasurement of Price Adjustment Shares liability


      --


      --


      --


      173,051

      Decrease (increase) in trade receivables


      4,654


      10,263


      (15,781)


      (5,829)

      Increase in deferred revenue


      33,156


      17,255


      49,768


      22,317

      Increase in other non-current assets


      (8,329)


      (47)


      (6,936)


      (341)

      Decrease (increase) in prepaid expenses and other
      current assets


      2,546


      (2,885)


      5,614


      3,201

      Changes in operating lease right-of-use assets


      1,162


      1,450


      4,585


      5,335

      Changes in operating lease liability


      3,150


      (1,278)


      547


      (4,839)

      Decrease in inventories


      1,284


      746


      1,632


      982

      Decrease in trade payables


      5,442


      3,917


      4,943


      2,755

      Increase in other accounts payable and accrued expenses


      6,810


      11,722


      4,248


      17,586

      (Decrease) increase in other long-term liabilities


      (2,571)


      (928)


      (2,015)


      880

      Net cash provided by operating activities


      86,811


      65,967


      173,544


      132,171










      Cash flows from investing activities:









      Purchases of property and equipment


      (3,956)


      (3,178)


      (13,225)


      (8,566)

      Cash paid in conjunction with acquisitions, net of
      acquired cash


      (147,456)


      --


      (147,456)


      (2,748)

      Purchase of Intangible assets


      --


      (1,139)


      --


      (2,043)

      Investment in marketable securities


      (126,028)


      (15,079)


      (321,231)


      (127,789)

      Proceeds from maturities of marketable securities


      34,772


      10,985


      152,992


      59,971

      Proceeds from sales of marketable securities


      28,643


      --


      59,809


      --

      Investment in short-term deposits


      (88,000)


      (39,000)


      (187,000)


      (207,000)

      Redemption of short-term deposits


      55,914


      31,462


      187,861


      138,702

      Net cash used in investing activities


      (246,111)


      (15,949)


      (268,250)


      (149,473)










      Cash flows from financing activities:


















      Exercise of options to shares


      1,022


      5,756


      20,097


      17,265

      Proceeds from Employee Share Purchase Plan


      1,318


      974


      4,956


      3,344

      Exercise of Warrants


      --


      --


      --


      53

      Redemption of Warrants


      --


      --


      --


      (11)

      Net cash provided by financing activities


      2,340


      6,730


      25,053


      20,651










      Net (decrease) increase in cash and cash equivalents


      (156,960)


      56,748


      (69,653)


      3,349

      Net effect of Currency Translation on cash and cash
      equivalents


      56


      (1,438)


      2,451


      (1,207)

      Cash and cash equivalents at beginning of period


      281,361


      136,349


      191,659


      189,517

      Cash and cash equivalents at end of period


      $           124,457


      $           191,659


      $         124,457


      $         191,659










      Supplemental cash flow information:









      Income taxes paid (received)


      $                2,838


      $                3,801


      $               (549)


      $             7,706

      Non-cash activities









      Operating lease liabilities arising from obtaining right-of-
      use assets


      $              (1,987)


      $                     53


      $           11,154


      $             1,884

      Reclassification and exercise of public and private
      Warrants


      $                      --


      $                      --


      $                   --


      $         164,770

      Reclassification and release of Restricted Sponsor Shares


      $                      --


      $                      --


      $                   --


      $         113,136

      Reclassification and issuance of Price Adjustment Shares


      $                      --


      $                      --


      $                   --


      $         254,766

      Cellebrite DI Ltd. 
      Reconciliation of GAAP to Non-GAAP Financial Information
      (U.S. Dollars in thousands, except share and per share data)



      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Cost of revenue

      $          19,691


      $          17,624


      $          75,172


      $          62,593

      Less:








      Share-based compensation

      775


      575


      3,180


      2,227

      Amortization of intangible assets

      881


      --


      881


      --

      Acquisition-related costs

      --


      --


      --


      2

      Non-GAAP cost of revenue

      $          18,035


      $          17,049


      $          71,111


      $          60,364


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Gross profit

      $        109,130


      $          91,425


      $        400,503


      $        338,610

      Share-based compensation

      775


      575


      3,180


      2,227

      Amortization of intangible assets

      881


      --


      881


      --

      Acquisition-related costs

      --


      --


      --


      2

      Non-GAAP gross profit

      $        110,786


      $          92,000


      $        404,564


      $        340,839


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Operating expenses

      $          88,325


      $          75,698


      $        334,023


      $        281,704

      Less:








      Share-based compensation

      11,222


      8,694


      41,712


      28,348

      Amortization of intangible assets

      1,227


      864


      4,018


      3,349

      Acquisition-related costs

      1,588


      --


      3,818


      219

      Executive severance costs

      --


      1,068


      574


      1,068

      Non-GAAP operating expenses

      $          74,288


      $          65,072


      $        283,901


      $        248,720


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Operating income

      $          20,805


      $          15,727


      $          66,480


      $          56,906

      Share-based compensation

      11,997


      9,269


      44,892


      30,575

      Amortization of intangible assets

      2,108


      864


      4,899


      3,349

      Acquisition-related costs

      1,588


      --


      3,818


      221

      Executive severance costs

      --


      1,068


      574


      1,068

      Non-GAAP operating income

      $          36,498


      $          26,928


      $        120,663


      $          92,119


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Net income (loss)

      $          21,261


      $          19,269


      $          78,326


      $      (283,007)

      Share-based compensation

      11,997


      9,269


      44,892


      30,575

      Amortization of intangible assets

      2,108


      864


      4,899


      3,349

      Acquisition-related costs

      1,588


      --


      3,818


      221

      Executive severance costs

      --


      1,068


      574


      1,068

      Tax income

      (260)


      (4,347)


      (2,003)


      (4,049)

      Finance expense from financial derivatives

      --


      --


      --


      349,604

      Non-GAAP net income

      $          36,694


      $          26,123


      $        130,506


      $          97,761









      Non-GAAP Earnings per share:








      Basic

      $               0.15


      $               0.11


      $               0.54


      $               0.45

      Diluted

      $               0.14


      $               0.10


      $               0.51


      $               0.42









      Weighted average shares outstanding:








      Basic

      245,282,244


      233,248,045


      241,626,316


      209,471,827

      Diluted

      257,274,507


      250,539,405


      254,677,860


      227,258,731


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Net income (loss)

      $          21,261


      $          19,269


      $          78,326


      $      (283,007)

      Financial (income) expense, net

      (5,466)


      (4,170)


      (24,198)


      332,890

      Tax expense

      5,010


      628


      12,352


      7,023

      Share-based compensation

      11,997


      9,269


      44,892


      30,575

      Amortization of intangible assets

      2,108


      864


      4,899


      3,349

      Acquisition-related costs

      1,588


      --


      3,818


      221

      Depreciation expenses

      1,833


      1,865


      6,968


      7,258

      Executive severance costs

      --


      1,068


      574


      1,068

      Adjusted EBITDA

      $          38,331


      $          28,793


      $        127,631


      $          99,377


















      For the three months ended


      For the year ended


      December 31,


      December 31,


      2025


      2024


      2025


      2024


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Net cash provided by operating activities

      $          86,811


      $          65,967


      $        173,544


      $        132,171

      Less:








      Purchases of property and equipment

      (3,956)


      (3,178)


      (13,225)


      (8,566)

      Free cash flow

      $          82,855


      $          62,789


      $        160,319


      $        123,605

      Free cash flow margin

      64.3 %


      57.6 %


      33.7 %


      30.8 %

      Cellebrite DI Ltd. 
      Reconciliation of GAAP to Non-GAAP Financial Information
      (U.S. Dollars in thousands, except share and per share data)



      December 31


      December 31


      2025


      2024


      (Unaudited)


      (Unaudited)

      Total ARR

      $           480,760


      $           395,899

      ARR related to acquisitions

      16,078


      --

      Organic ARR

      $           464,682


      $           395,899

      SOURCE Cellebrite

      Modal title

      Profil de l'entreprise

      Cellebrite

        Autres communiqués de la compagnie

      • Cellebrite présentera ses résultats financiers du troisième trimestre 2026 le 12 novembre 2026

      • Cellebrite nomme Rogerio Rizzi au poste de vice-président exécutif chargé de la stratégie et du développement de l'entreprise

      • L'élan donné par Genesis dynamise la version automnale de Cellebrite : davantage de preuves, une analyse plus approfondie, un accès plus large aux enquêtes

      Communiquer avec PR Newswire

      • 877-269-7890
        De 7 h 30 à 18 h 30 (HE)
      • Devenir un client
      • Demander une démo
      • Bureaux d'édition
      • Partenariats
      • Renseignements généraux
      • Médias
      • Bureaux mondiaux

      Produits

      • Découvrez la plateforme
      • Planifier des campagnes
      • Créer avec l'IA
      • Diffuser des communiqués
      • Mesurer vos résultats
      • Amplifiez le contenu
      • Relations investisseurs

      À propos

      • À propos de Cision
      • Carrières
      • Énoncé d'accessibilité

      Services

      • Toutes les nouvelles
      • Connexion à la plateforme
      • mon CNW
      • Protection des données

      Ne pas vendre ou partager mes informations personnelles:

      • Soumettre à [email protected] 
      • Appelez gratuitement notre département de la protection de la vie privée: 877-297-8921

      Communiquer avec Cision

      Produits

      À propos

      Services
      • Toutes les nouvelles
      • Comms Cloud Nouvelle Génération
      • Cision Communications Cloud®
      • Plateforme
      • mon CNW
      877-269-7890
      de 8h00 à 22h00
      • Modalités d'utilisation
      • Politique sur la sécurité des données
      • Plan du site
      • Paramètres de cookies
      • Énoncé d'accessibilité
      © Groupe CNW Ltée 2026 Tous droits réservés. Une société Cision.